---
schema_version: "secwatch.filing_event.v1"
accession: "0000879169-25-000059"
form_type: "8-K"
ticker: "INCY"
cik: "0000879169"
company_name: "INCYTE CORP"
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T11:53:38.834749+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Incyte settles JAKAFI royalty dispute with Novartis; pays $280M vs $537M accrued

## Summary
- Settlement resolves litigation over royalty duration under 2009 Collaboration and License Agreement.
- Incyte to pay Novartis $280M; had $537.1M accrued as of March 31, 2025.
- Royalty rate on future U.S. JAKAFI net sales reduced by 50% effective Jan 1, 2025.
- Reduced royalty for Q1 2025 is ~$14.9M; $242.2M difference to be recorded in Q2 2025.
- Settlement eliminates contingent liability and lowers future royalty expense.

## SEC filing metadata
- accession: 0000879169-25-000059
- form_type: 8-K
- ticker: INCY
- cik: 0000879169
- company_name: INCYTE CORP
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/879169/000087916925000059/0000879169-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/879169/000087916925000059/incy-20250511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000879169-25-000059
- JSON: https://secwatch.observer/filing/0000879169-25-000059.json
- Plain text: https://secwatch.observer/filing/0000879169-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.